These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32005275)

  • 1. Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
    de Ruijter TC; van der Heide F; Smits KM; Aarts MJ; van Engeland M; Heijnen VCG
    Breast Cancer Res; 2020 Jan; 22(1):13. PubMed ID: 32005275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
    Sheng X; Guo Y; Lu Y
    Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
    Sharma G; Mirza S; Yang YH; Parshad R; Hazrah P; Datta Gupta S; Ralhan R
    Cell Oncol; 2009; 31(6):487-500. PubMed ID: 19940364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
    Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
    Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
    Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
    Callahan CL; Wang Y; Marian C; Weng DY; Eng KH; Tao MH; Ambrosone CB; Nie J; Trevisan M; Smiraglia D; Edge SB; Shields PG; Freudenheim JL
    Epigenetics; 2016 Sep; 11(9):643-652. PubMed ID: 27245195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
    Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
    Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients.
    Fujita N; Nakayama T; Yamamoto N; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Morimoto K; Tamaki Y; Noguchi S
    Oncology; 2012; 83(5):273-82. PubMed ID: 22964822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer.
    Vu TL; Nguyen TT; Doan VTH; Vo LTT
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1887-1893. PubMed ID: 30049201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
    Pirouzpanah S; Taleban FA; Mehdipour P; Atri M
    J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
    PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
    Gaudet MM; Campan M; Figueroa JD; Yang XR; Lissowska J; Peplonska B; Brinton LA; Rimm DL; Laird PW; Garcia-Closas M; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3036-43. PubMed ID: 19861523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
    Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.
    Cho YH; Shen J; Gammon MD; Zhang YJ; Wang Q; Gonzalez K; Xu X; Bradshaw PT; Teitelbaum SL; Garbowski G; Hibshoosh H; Neugut AI; Chen J; Santella RM
    Breast Cancer Res Treat; 2012 Jan; 131(1):197-205. PubMed ID: 21837480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women.
    Wong CM; Anderton DL; Smith-Schneider S; Wing MA; Greven MC; Arcaro KF
    Epigenetics; 2010 Oct; 5(7):645-55. PubMed ID: 20716965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.